ArticleChemistry, an Asian journal2015
Aptamer CaCO3 nanostructures: a facile, pH-responsive, specific platform for targeted anticancer theranostics.
Article in Chemistry, an Asian journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 47 citations in OpenAlex.
- Lysosome-centered nanomedicine for cancer therapy: mechanisms, materials, and modalities.Journal of nanobiotechnology · 2026Review
- Recent Advances of Calcium Carbonate Nanoparticles for Biomedical Applications.Bioengineering (Basel, Switzerland) · 2022Review
- Biguanide-Based Synthesis of 1,3,5-Triazine Derivatives with Anticancer Activity and 1,3,5-Triazine Incorporated Calcium Citrate Nanoparticles.Molecules (Basel, Switzerland) · 2021Article
- Aptamers Chemistry: Chemical Modifications and Conjugation Strategies.Molecules (Basel, Switzerland) · 2019Review
- Molecular Engineering of Functional Nucleic Acid Nanomaterials toward In Vivo Applications.Advanced healthcare materials · 2019Review
- pH-dependent and cathepsin B activable CaCOInternational journal of nanomedicine · 2019Article
- Aptamer-based targeted therapy.Advanced drug delivery reviews · 2018Review
- pH-Control in Aptamer-Based Diagnostics, Therapeutics, and Analytical Applications.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Ra-224 labeling of calcium carbonate microparticles for internal α-therapy: Preparation, stability, and biodistribution in mice.Journal of labelled compounds & radiopharmaceuticals · 2018Article
- Supramolecular aptamer nano-constructs for receptor-mediated targeting and light-triggered release of chemotherapeutics into cancer cells.Nature communications · 2018Article
- Core-shell NaGdFScientific reports · 2017Article
- Advances in the development of aptamer drug conjugates for targeted drug delivery.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017Review
- Application of aptamers in diagnostics, drug-delivery and imaging.Journal of biosciences · 2016Article
- An enhanced chemiluminescence bioplatform by confining glucose oxidase in hollow calcium carbonate particles.Scientific reports · 2016Article
- Aptamer-Functionalized Nanoparticles as "Smart Bombs": The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment.Targeted oncology · 2015Review
- Aptamer-Drug Conjugates.Bioconjugate chemistry · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
The application of cancer theranostics depends on the development of multifunctional nanostructured platforms for accurate cell targeting and controlled drug release, imaging, and therapy. Herein, a comprehensive, easily fabricated anticancer theranostic platform with a high drug-loading capacity, termed an aptamer-functionalized calcium carbonate (CaCO3 ) nanostructure (apt-CCN), is reported. Flow cytometry and confocal fluorescence microscopy studies demonstrate that apt-CCNs can specifically bind to target cancer cells, but not to control cells, and that they possess highly efficient internalization to target cancer cells. This smart nanostructure selectively reaches the lysosomes through receptor-mediated endocytosis and is responsive to the relatively low lysosome pH (4.5-5.5), which facilitates the release of doxorubicin. The apt-CCN platform offers targeted and efficient drug transport, as well as target-specific delivery of imaging agents for cancer diagnosis and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.